24% growth masks sequential margin collapse and execution risks
Sasken delivered strong YoY growth and order bookings, but sequential PAT fell 18.9% and Product Solutions margins halved. The real story lies in what management declined to guide on.
The quarter in context
+24% YoY
₹339.2 Cr; +1.6% QoQ
+135% YoY
₹23.5 Cr; -18.9% QoQ
5.9%
down 310 bps QoQ from 12.8%
$47M TCV
$34M new wins; 5 new logos
Sasken's headline reads like a growth story: ₹339 crore revenue, up 24% year-on-year, with strong order bookings of ₹47 million TCV in Q1. Profit jumped 135% YoY to ₹23.5 crore. But here's the tension: sequential PAT fell ₹2.9 crore (−18.9%), and Product Solutions gross margin halved from 12.8% to 5.9% in a single quarter. The YoY narrative masks a sharp deterioration in underlying execution.
Where the sequential decline came from
The PAT decline from Q4 to Q1 despite revenue growth reflects a structural shift, not a one-time event. Management attributed the margin collapse in Product Solutions to three factors: memory pricing (where Sasken acts as a pass-through but still absorbs carry margin), a shift in program mix toward lower-margin silicon productization, and component cost inflation. Software Services, by contrast, improved 240 bps to a 30.6% gross margin, lifting utilization to 85%. The two segments are moving in opposite directions — and the company has no timeline for Product Solutions recovery.
The product mix changed. Our silicon business is moving towards productization and that has an impact on the margins.
Management claims vs. what holds up
Revenue ₹339 Cr, up 24% YoY, 1.6% QoQ
SupportedRevenue ₹339.2 Cr, +24.0% YoY, +1.6% QoQ — exact match
Product Solutions margins stabilizing, expect improvement through year
ContradictedGross margin fell 310 bps QoQ to 5.9%, halved from Q4's 12.8%. Sequential revenue also fell 3.9%.
Disciplined profitable growth, margin improvement ahead
OverstatedYoY PAT +135% but QoQ −18.9%; product gross margin halved. CFO refused margin guidance.
60x4x3 strategy on track — 60 $4M+ customers in 3 years
ContradictedOnly 6 customers at $4M+ after 10 of 12 planned quarters (~75% of timeframe spent, ~10% of target achieved). MD said 3-year frame is 'metaphoric' and may take 1–2 more years.
Strong order backlog converts to stable near-term revenue
Partial$47M TCV Q1 bookings ($34M new wins) must convert to revenue in Q2–Q4. $40M ACV represents ~1.2 quarters of run-rate revenue; risk of lumpy conversion.
What changed on this call
60x4x3 timeline extended: MD said 3-year goal is 'metaphoric' and may take '1–2 more years'
Product Solutions margin structure reset: halved to 5.9%, attributed to silicon productization and memory/component costs
No FY27 margin guidance issued: CFO explicitly declined to provide EBITDA or PAT margin targets
Hyperscaler wins booked: agentic AI, LLM validation, and intelligent testing engagements from two different hyperscalers
Silicon Incubation Center opened in Hubballi; new Hyderabad center for engineering talent
Customer base grew from 79 to 93 active; 5 new logos in Q1
Operating cash flow remains negative for 2 years; CFO said 'work in progress' with large cash consumption expected in FY27
The bull-bear ledger
Bull: 24% YoY revenue growth; strong order bookings ($47M TCV, $34M new wins); customer base expanded 14 customers YoY to 93
Bull: Chip-to-Cognition strategy is differentiated; hyperscaler AI engagements are high-margin, long-duration wins
Bull: Software Services segment growing +24.3% YoY with improving margins (30.6%, +240 bps); utilization at 85%
Bear: Sequential PAT down ₹2.9 Cr (−18.9%) despite YoY growth; YoY narrative masks quarterly deterioration
Bear: Product Solutions gross margin halved QoQ to 5.9%; no recovery timeline provided by management
Bear: 60x4x3 strategy severely lagging: only 6 of 60 customers at $4M+ threshold after 10 quarters (75% time elapsed, 10% progress achieved)
Bear: Operating cash flow negative for 2 years; expected to remain negative through FY27 due to Borqs integration and working capital investments
Bear: Management refused FY27 margin guidance; signals uncertainty on recovery timeline and execution confidence
Risks, ranked by severity to a holder
Product Solutions margin structure deterioration
HighGross margin halved from 12.8% to 5.9% QoQ due to silicon productization, memory, and component costs. If persists, will drag consolidated OPM. No recovery target or timeline provided.
60x4x3 strategy severely lagging execution
HighOnly 6 of 60 target customers at $4M+ revenue run-rate after 10 quarters (75% planned time elapsed). MD reset expectation to '1–2 more years,' signaling 50%+ delay. Core growth strategy credibility damaged.
Operating cash flow negative for 2 years; expected to remain negative FY27
HighDespite ₹339 Cr revenue and ₹23.5 Cr PAT, cash flow remains negative due to Borqs integration, working capital, and inventory build. No clear path to cash-flow positive announced.
Borqs profitability break-even at $12M quarterly (~₹100 Cr annualized) not yet visible
MediumBorqs was promised to break even at $60–70M annualized; now reset to $12M quarterly. At current 5.9% Product Solutions margins, scaling Borqs profitably requires either significant revenue growth or substantial margin recovery. Both uncertain.
Management deflection on margin guidance and recovery timeline
MediumCFO explicitly refused to provide FY27 margin targets after analysts asked three times. Signals either internal uncertainty or unwillingness to commit. Reduces transparency.
Order bookings conversion risk
Medium$47M Q1 TCV bookings represent ~1.2 quarters of revenue. Must convert evenly in Q2–Q4 to avoid lumpy revenue. Silicon orders are multi-year; conversion timeline unclear.
How the street is positioned
Initial positive reaction, but stock remains under pressure. Sasken's result announcement (Jul 31, 2026) triggered a day-1 pop of +4.42%, which extended to +8.26% by day 3 and held at +6.76% by day 5. The market favored the YoY growth and order bookings, treating the sequential PAT decline and margin collapse as temporary noise. However, the stock at ₹1,971.4 sits 29% below its all-time high and below its SMA50 (₹2,058.28), suggesting investors remain cautious on the multi-quarter outlook. RSI of 59.9 (neutral) indicates no overbought condition.
Ownership and flows: FII ownership ticked up to 19.11% (gain of 0.57pp QoQ), and DII inched higher to 1.39% (gain of 0.34pp). The moves are modest, suggesting institutional investors are nibbling on weakness but not aggressively accumulating. Promoter holding remains stable at 42.95%. Bulk deal activity over the past 6 months shows mixed trading — no large insider-linked selling near recent highs, but no concentrated buying either. The lack of institutional conviction despite the pop is telling: the market bought the print but hasn't committed the capital to push the stock closer to its prior high.
Valuation context: At ₹1,971.4, the stock trades 29% below ATH and +98.93% above the 52-week low (₹991), suggesting it is no longer cheap. The 52-week range (₹991–₹2,780.2) shows the stock's volatility. The stock sits above SMA20 (₹1,886.35) but below SMA50, a mild bearish tilt. The market has priced in some recovery narrative (the pop) but not enough to erase the discount from recent highs — a clear signal that sequential deterioration and margin questions are a concern.
1 · Q2 Product Solutions margin stabilization
Did the 5.9% gross margin bottom in Q1, or will it compress further in Q2? Management promised 'full-year stabilization' but no target. Watch for sequential improvement; if margins compress further, the structural headwind is more severe than claimed.
2 · $47M TCV Q1 bookings conversion to revenue
Management must demonstrate even conversion of the $34M new wins across Q2–Q4. If conversion is lumpy (e.g., heavy in one quarter), it suggests customer bookings are volatile or multi-year deliveries are unpredictable. Also watch the ACV sustainability ($40M for 12 months is critical).
3 · Operating cash flow inflection
Negative for 2 years and expected to worsen in FY27. Management must articulate a path to cash-flow positive; without it, the company's ability to fund growth, shareholder returns, or debt repayment is constrained. Watch for any update on cash burn rate or timeline to positive OCF.
The verdict
Sasken delivered on headline growth (24% YoY, ₹339 Cr revenue) and order bookings ($47M TCV). But the quarter reveals two deeper issues: sequential deterioration masked by year-on-year comparisons, and structural margin pressure in the core Product Solutions business. The 60x4x3 strategy, once a key pillar, is now only 10% achieved after 75% of planned time; management reset the timeline to '1–2 more years,' effectively doubling the goal. Operating cash flow remains negative after 2 years, with no clear recovery plan. Management's refusal to guide on FY27 margins suggests internal uncertainty, not conservative positioning.
The market's day-1 pop (+4.42%) reflects enthusiasm for growth and hyperscaler wins, but the stock's position 29% below ATH and below SMA50, combined with modest institutional accumulation (FII +0.57pp), signals caution. Investors bought the print but didn't commit capital to push it back to recent highs.
Rating: HOLD. The company is not in distress — growth is real, the strategy is sound, and hyperscaler engagements are valuable. But execution risk is material: Product Solutions margins are broken (5.9%), 60x4x3 is lagging severely, and cash flow is underwater. The quarter is a steady deceleration, not a step-change, but one that should concern holders. The number to track from here is sequential product margin recovery in Q2; if it stabilizes or improves, the bear case weakens. If it compresses further, the structural nature of the headwind is confirmed, and repricing risk rises. Until then, patience over conviction.
Published 2026-08-17 | Region: IN | Quarters tracked: Q1 FY-2027 | Confidence: 6/10
Informational and educational content only. Not investment advice.